

## SPECIAL TOPIC

# Molecular Imaging in Nanotechnology and Theranostics

Chrysafis Andreou,<sup>1</sup> Suchetan Pal,<sup>1</sup> Lara Rotter,<sup>2</sup> Jiang Yang,<sup>1</sup> Moritz F. Kircher<sup>1,3,4</sup>

<sup>1</sup>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

<sup>2</sup>Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

<sup>3</sup>Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

<sup>4</sup>Department of Radiology, Weill Cornell Medical College, New York, NY, 10065, USA

### Abstract

The fields of biomedical nanotechnology and theranostics have enjoyed exponential growth in recent years. The “Molecular Imaging in Nanotechnology and Theranostics” (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was created in order to provide a more organized and focused forum on these topics within the WMIS and at the World Molecular Imaging Conference (WMIC). The interest group was founded in 2015 and was officially inaugurated during the 2016 WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nanoconstructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3–5 years, in order to provide the reader with an intuition of what is “in the pipeline” and has potential for clinical translation in the near future.

**Key words:** Nanoparticles, Imaging, Theranostic, WMIS, MINT

## Introduction

With unique properties endowed by their size, modular structure, and functionalization abilities, biomedical nanoparticles are being unremittingly developed and used in biomedicine. In medical imaging, they serve as contrast agents—detectable with multiple modalities simultaneously—and give rise to new techniques for the ever-richer acquisition of molecular information. Some are already employed clinically as therapeutics, or delivery vehicles for pharmaceuticals, since they serve to reduce systemic side effects [1]. Targeted drug and gene delivery

strategies and stimuli-responsive nanoparticle therapies are in clinical trials [2]. Modular and versatile, unifying imaging with therapy, nanoparticles are becoming true theranostic agents.

Compared to small molecules, nanoparticles feature notable advantages as theranostic agents, summarized in Fig. 1: (1) their modular structure and surface modifications enable multiple functionalities (decreased immunogenicity, targeting, multimodal imaging, therapy, and controlled pharmacokinetics); (2) specific tissues can be targeted passively (e.g., reticuloendothelial system or kidneys), as can many tumors through the “enhanced permeability and retention” (EPR) effect; (3) nanoparticles can respond to their microenvironment or to external stimuli to provide therapy and contrast only where needed [3]; and (4) different

Correspondence to: Moritz Kircher; e-mail: kirchem@mskcc.org




Fig. 1. Through their modular structure, nanoparticles can incur specific biologic interactions and deliver targeted therapy using intrinsic or external stimuli.

types of therapy can be elicited by the nanoparticles. These features render nanoparticles as peerless imaging agents using traditional medical imaging and enable the development of new modalities and theranostic applications. Many strategies have been reported for creating biomedical imaging nanoparticles using a variety of materials, and this has generated a virtual cornucopia of easily obtainable nanoparticle agents. A non-exhaustive selection of references, tabulated by material, imaging modality, and therapy is presented in Table 1.

## Imaging

Among the first nanoparticle constructs to allow molecular imaging were superparamagnetic iron oxide nanoparticles (SPIONs), used for contrast generation with magnetic resonance imaging (MRI) [4, 5]. The current emphasis lies on their clinical translation, especially given the renaissance spurred by ferumoxytol, which is now FDA-approved for systemic injection as an iron replacement therapy (trade name Feraheme). As a member of the family of ultrasmall superparamagnetic iron oxide nanoparticles (USPIOs), ferumoxytol causes regional T1 and T2\* shortening *in vivo*, leading to signal enhancement or loss on conventional MR pulse sequences [6]. Ferumoxytol has shown promise in diverse areas such as noninvasive identification of type 1 diabetes [7], determining the severity of neurological diseases [8], imaging of tumor-associated macrophages (TAMs) [9], cell tracking [10], or whole-body cancer staging [11]. A recent and very exciting discovery was the finding that ferumoxytol may have an intrinsic, anticancer

therapeutic effect: intravenous ferumoxytol administration was shown to prevent metastases to the liver. This phenomenon is thought to be due to pro-inflammatory macrophage (M1) polarization in tumor tissues [12]. Such discoveries bear the hope that other nanoparticle agents may also harbor such unexpected theranostic effects.

Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are noninvasive imaging modalities frequently used in clinical settings for oncology, neuroscience, cardiology, etc. [13, 14] using radioactive nuclides conjugated to small molecules, e.g., 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) or antibodies. Recently, nanoparticles labeled with radiotracers were found to be very promising—particularly in cancer imaging—in preclinical studies because of three major advantages: (1) the EPR effect; (2) high surface-to-volume ratio of the nanoparticles allowing high density radiolabeling either using chelators (such as DOTA), chelator-free strategies, or intrinsic labeling during synthesis [15]; and (3) complementary multimodal imaging. Many different radionuclide–nanoparticle combinations have been reported; but smaller, rapidly clearable nanoparticles with fast decaying radiolabels are ideal for potential clinical translation. Nanoparticles with Cu-64 ( $t_{1/2} = 12.7$  h) were shown to allow *in vivo* imaging up to 48 h [16–21]. Ultra-small chelator-free renally clearable Cu-64-labeled Cu nanoclusters were reported for imaging in orthotopic lung cancer mouse models [22]. In another study, Cu-64-based liposomes were used to assess the EPR effect in canine cancer models, suggesting high inter-tumoral heterogeneity of EPR-based uptake [23]. Other radioisotope–nanoparticle combinations have been employed for different imaging purposes, including Ga-68 ( $t_{1/2} = 68$  min), Zr-89 ( $t_{1/2} = 3.3$  days), In-111 ( $t_{1/2} = 2.8$  days), and Au-198 ( $t_{1/2} = 2.69$  days) [24–30]. Recently, Zr-89 was used to label soft, polymeric, and lipoprotein nanoparticles for imaging of macrophages in atherosclerotic plaques and tumors [31–33]. Important steps towards clinical translation of PET nanoparticles are being carried out using C-dots (“Cornell dots”) labeled with I-124 ( $t_{1/2} = 4.18$  days), showing excellent localization and no toxicity in metastatic melanoma patients [34, 35].

Fluorescent nanoparticles (FNPs), with intrinsic fluorescence or loaded with fluorescent dyes, are being investigated as imaging agents due to their advantages over small molecule dyes, namely, improved specificity (by active or passive targeting [36, 37]), increased circulation time (by evading immune detection and renal clearance), and smart activation (by pH dependency or enzymatic activity) as well as increased signal intensity [36, 38]. FNPs have been reportedly used for sentinel lymph node (SLN) and solid tumor detection, image-guided tumor surgery with real-time feedback, and monitoring of drug delivery [36, 39]. Also, fluorescent quantum dots and gold nanoparticles (passivated with polyethylene glycol (PEG) or silica) [36, 39] can be combined with complementary imaging agents like gadolinium [39, 40], organic dyes [39], polymeric dots [39, 41], or



Fig. 2. Nanoparticles of different materials, with many applications available at our fingertips.

fluorescent proteins [39, 42, 43]. Quantum dots are of particular interest due to their broad absorption and size-tunable emission spectra, making them suitable for multiplexing [37, 44] and less susceptible to photobleaching compared to broadly used organic dyes [37].

A new generation of fluorogens has been introduced to bioimaging with FNPs, exhibiting aggregation-induced emission (AIE) [45]. AIE overcomes aggregation-induced quenching and allows for higher concentration of fluorogens on the NP while also reducing photobleaching [45]. However, due to the fluorogens' broad emission spectra, it is less suitable for multiplexing, instigating some groups to work on narrowing the emission spectra via Förster resonance energy transfer [46]. Although fluorescence imaging is complicated by high false-positive rates [47], improvements in specificity have been reported, leading to higher levels of complete tumor resection [48].

Raman imaging—a spectroscopic optical imaging technique—with surface enhanced (resonance) Raman scattering nanoparticles (SERS NPs) shows much potential for *in vivo* imaging of cancer [49]. Unlike fluorescent agents, SERS NPs do not suffer from significant background from endogenous molecules or photobleaching [50]. In fact, the endogenous Raman signals can be used to generate surface topology on which the specific signals can

be mapped without interference [51]. With their low detection threshold and high signal specificity, SERS NPs were shown to delineate tumors—and even premalignant lesions—passively through the EPR effect [52]. Nanoparticle sequestration by the RES allows for imaging of SLNs [53] and tumors in the liver and spleen [50]. SERS NPs were reported to delineate tumors preoperatively and intraoperatively [54], as well as detecting microscopic tumors and metastatic foci in glioblastoma, ovarian cancer, and lung metastases [55–59]. Given their potential significance in tumor imaging and nontoxic composition, the timely translation of SERS NPs into the clinic could represent a fundamental improvement in patient morbidity and mortality.

Nanoparticles can be engineered to allow “hybrid” imaging methods, where excitation and detection occur through distinct physical processes. For example, in photoacoustic imaging (PAI), pulses of light excite the contrast agent, which in turn produces a mechanical response, detected as ultrasound [60]. Images are obtained noninvasively, deeper within tissues and with higher spatial resolution compared to purely optical imaging techniques. Nanoparticles based on plasmonic [61–66], polymeric [67–72], and other materials [73–87] have all shown great potential in preclinical studies, combining photoacoustic detection with photothermal and photodynamic therapies (PTT and PDT). However, nanoparticles based on iron oxide [88–90] or silica [91] have a higher likelihood for clinical translation as similar materials are already approved for use in humans. Magnetically actuated photoacoustically active nanoparticles are of particular interest, as they allow more specific detection through magnetic actuation [92].

Some charged particles produced by radionuclide decay emit visible light, referred to as Cerenkov luminescence (CL) [93], already demonstrated for cancer imaging in humans using [ $^{18}\text{F}$ ]FDG [94]. Nanoparticle-based agents bring new potential to this emerging modality, allowing for more specific imaging [95–97] and therapy [98–100], while active or passive targeting [101] can map receptors [102] or enzymes [103] of interest. As nanoparticles for PET imaging are translated to the clinic, CL may provide additional, complementary information to the benefit of the patient.

## Therapy

Nanoparticles have great potential as therapeutic agents, delivering drugs, genes, or other forms of therapy, with many examples of clinical success [1]. In the paradigm set by Doxil, nanoparticles can be engineered to encapsulate pharmaceuticals (such as doxorubicin (DOX)) and release them at targeted sites, reducing systemic toxicity and improving pharmacokinetic profiles. In a newer scheme, DOX-conjugated poly(lactic-co-glycolic acid) (PLGA) was loaded into an injectable nanoparticle generator spontaneously releasing nanoparticles upon pH stimulation, which are later cleaved into DOX within the cell to avoid drug

efflux pumps, showing enhanced efficacy in metastatic breast cancer models over free DOX [104]. Ultrasmall [ $^{64}\text{Cu}$ ]-PEG-melanin nanoparticles loaded with FDA-approved multikinase inhibitor sorafenib provide PET-PAI image-guided chemotherapy in liver xenograft models [105]. Recently, siRNA-loaded nanoparticles were employed in various settings, such as gene delivery into lung cancer cells—but not normal cells—without targeting ligands [106], transdermal application for suppressing EGFR expression and downstream ERK signaling in mice and humans with no clinical or histological toxicity [107], and increasing progression-free survival in murine acute kidney injury models and nonhuman primates [108].

PTT employs heat to destroy cancer cells and nanomedicine can substantially facilitate this process. AuroShell is the first demonstrated exogenous vis-NIR light-absorbing nanoparticle for photothermal tumor ablation and optical coherence tomography (OCT) [109] and was extensively investigated in murine and canine models of various cancer types [110–112]. Pilot clinical studies are being conducted in head and neck cancer (NCT00848042), lung cancer (NCT01679470), and prostate cancer (NCT02680535). Gold nanoparticles with radiofrequency waves can also induce PTT [113, 114]. For PDT therapy, Cerenkov luminescence can activate transferrin-coated  $\text{TiO}_2$  photosensitizer nanoparticles and mediate tumor remission by generating free radicals and immune cell infiltration [115]. NIR PDT is achievable using photosensitizing silica-coated upconversion nanoparticles for deeper tissue penetration than visible light [116]. Aminosilane-coated iron oxide (NanoTherm), significantly polarized under external magnetic fields to selectively ablate tumors by heat generation, is undergoing clinical trials in the USA [117–119]. FDA-approved SPIONs were also found to inhibit tumor growth by hyperthermia under magnetic fields at preclinical levels [120–122]. Such integration of multiple functions and modalities is a unique characteristic of nanoparticles that will make them invaluable for detection and therapy in a wide variety of diseases.

Ultrasound (US) can promote nanoparticle accumulation and drug release in tumors through cavitation and is reported to mediate nanoparticles crossing even intact blood–brain barriers [123]—see mini-review on US molecular imaging by Caskey in this issue. Nanoparticles as a sonoporation enhancer are advantageous over microbubbles (MBs) for their extravasation in capillaries and sustained activity. PEG-PDLA nanoparticles were used to overcome aqueous solubility barriers of paclitaxel under US guidance [124]. Polymer nanoparticle-stabilized MBs with embedded SPIONs provide MRI/US imaging and pulse-activated nanoparticle release [125]. Gas-generating docetaxel (DTX) and Cy5.5 dye-loaded polymeric nanoparticles in MBs offer fluorescence/US signal and are released at tumor sites upon ultrasound irradiation through bubble burst, with much higher contrast than clinically used Sonovue® and

Definity® and higher therapeutic effects than free DTX or without US activation [126].

Nanoparticles can also elicit immunotherapy. Besides the aforementioned hyperthermia effects, SPIONs were recently found to intrinsically inhibit tumor growth as a potential macrophage-modulating immunotherapy [12]. Adjuvant drug labeled liposome- and lipid-based nanoparticles covalently attached to cell surface for adoptive T cell therapy can markedly decrease tumor burden at preclinical setups [127]. PEG-PLGA nanoparticles encapsulated with indocyanine green (ICG) and TLR7 agonist R837 can generate tumor-associated antigens during PTT, and its combination therapy with anti-CTLA4 antibodies significantly inhibited metastasis in a 4T1 orthotopic model [128]. Carbon nanotube-PLGA nanocomplexes with high surface area were functionalized with T cell stimulating antigens for delivery of IL-2 at a dose much lower than clinically used to overcome adverse reactions. These nanocomplexes generate a large number of cytotoxic T cells and delay tumor growth in murine melanoma models [129].

PET-based nanoparticles are being perused as an alternative to traditional internal radiotherapy or brachytherapy as they allow even distribution within the tumor volume. Alpha emitters with long half-life like Ac-225 ( $t_{1/2} = 10$  days) are the preferred radionuclides for the formulation of radiotherapeutic nanoparticles [130, 131]. However, there is concern about the radioactivity of downstream decay processes. Recently, I-131 ( $t_{1/2} = 8$  days), often used for the treatment of thyroid cancer, has been integrated with iron oxide nanoparticles and polymeric nanoparticles for targeted therapy of hepatocellular carcinoma in mouse models [132, 133]. Lu-177 ( $t_{1/2} = 6.6$  days) has been utilized in lipid-calcium phosphate nanoparticles showing significant growth inhibition in subcutaneous xenograft tumor models [134]. There is also great deal of interest in using a nonradioactive module as a therapeutic partner in the formulation of PET nanoparticles. In a recent study, a Tc-99m-labeled ( $t_{1/2} = 6$  h), folic acid-targeted, multiwalled CNT nanoprobe has been developed using methotrexate as a therapeutic module showing an augmentation of the therapeutic efficacy of the drug in the presence of Tc-99m [135].

Metal nanoparticles can act as radiosensitizers, enhancing the efficacy of radiotherapy, e.g., renally clearable ultrasmall gold nanoclusters with high tumor uptake [136], or polymeric nanoparticles loaded with gold nanoparticles [137]. Gold nanoparticles in glioma models boosted overall survival in mice [138], as well as in head and neck cancer models [139], while silver nanoparticles produced similar results in glioma-bearing rats [140]. Therapeutic Pd-103–Au nanoseeds offer SPECT signal along with a radiotherapeutic effect of >80% tumor shrinkage [141]. I-131-doped CuS nanoparticles provide combined PTT and radiotherapy together with CT and gamma image guidance to treat 4T1 subcutaneous and metastatic tumors [142].



**Table 1.** Biomedical nanoparticles developed from a wide variety of materials recently reported for theranostic applications

	Noble metals	Other metals	Metal oxides	Semiconductors	Silica	Carbon	Polymers/ liposomes	Proteins	Other materials
Imaging									
MRI	[40, 54, 156]	[26, 28, 40, 87, 132, 157–160]	[6–12, 26, 28, 40, 117, 120, 122, 132, 157–159, 161–167]	[39, 40]	[54]	[40]	[125, 164]		[81, 168, 169]
PET/SPECT	[16, 17, 25, 29, 30, 40, 100, 101, 141, 170]	[24, 26, 28, 40, 157, 158, 171–173]	[24, 26, 28, 40, 157, 158, 161, 171–174]	[18, 40]	[20, 27, 34, 35]	[40, 108, 135]	[21, 23, 98, 101, 105, 133, 134]	[32, 175]	[22, 33, 130, 131, 134, 144, 168]
CT	[17, 30, 61, 64, 136–138, 141, 170]		[79, 117–119]	[18]	[20, 27, 35]		[61, 79, 137]		[134, 142, 144]
Optical	[36, 49, 50, 52–59, 145]	[36, 107, 116]	[36, 77, 115]	[19, 39]	[34, 35, 49, 50, 52–59, 155]	[108]	[38, 43, 77, 104, 106, 125, 126, 128, 145, 176]	[115, 175]	[144, 168]
Photoacoustic	[54, 61–66]	[78, 87]	[77, 79, 89, 90, 92]	[71, 72, 82–84]	[91]	[86, 150]	[43, 61, 66–68, 70–72, 74, 77–79, 82–84, 92, 105]	[75]	[73, 76, 80, 81, 85, 144]
Ultrasound									
Cerenkov	[30, 100, 101, 103, 170]	[24]	[24, 97, 102, 161, 174]	[18, 19]	[99]		[77, 125–126, 164]	[97]	[144, 177, 178]
Therapy									
Drug delivery									
Gene/siRNA delivery	[65]	[107]	[165]		[91]	[135]	[104, 105, 124, 126]		
Immunotherapy	[145]					[108]	[98, 104, 106, 145, 176]		
PTT/PDT	[100]	[87, 116, 173]	[12]	[72, 82, 83]	[99]	[129]	[128, 129]	[179]	
	[16, 62, 64, 66, 109–112, 145, 156]		[77, 79, 97, 115, 173]				[66, 72, 74, 77, 79, 82, 83, 128, 145]	[75, 97, 115]	[81, 85, 142]
Radiotherapy									
Externally actuated	[136–141]	[132]	[115, 117, 132]				[134, 137]	[115]	[142]
	[113, 114]		[117–120, 122]						

Nanoparticles with multiple functionalities are listed multiple times

## Future Directions

Nanoparticles are quickly becoming universal imaging agents, taking multimodal imaging to new heights [143, 144]. Soon, with advances in synthesis and standardization, the use of nanoparticle agents will become ubiquitous, seamless, and personalizable (see Fig. 2). Multiple treatments can be packaged within the same nanoparticle agent, for example, a prophylactic hydrogel patch containing fluorescently labeled targeted gold nanoparticles locally implanted into a tumor makes a triple combination therapy of siRNA against *Kras*, VEGF inhibitor delivery, and PTT available at the same time for colon cancer treatments [145]. Monitoring the nanoparticle distribution in the body, but also the therapeutic load delivery via imaging, is possible, for example via MRI [146, 147]. The next crucial step will be predicting their distribution even before administration, especially given the high variability of the EPR effect. Such prediction may take the form of “companion nanoparticles” [148] or computational models [149]. Bioderived nanoparticles, synthesized using “green chemistry” or cells [150–152], can expand the limits of biocompatibility and immune evasion through biomimicry [153]. Such biocompatible synthesis approaches could soon enable chemical manipulation of nanoparticles *in vivo* [154]. As nanoparticles transition to the clinic, they are investigated more deeply and new effects are discovered. For example, besides their role in intraoperative image-guided oncosurgeries, C-dots were recently observed to induce ferroptosis of cancer cells both *in vitro* and *in vivo* [155], and iron oxide nanoparticles were shown to reprogram TAMs to attack tumors [12].

## Conclusion

With many examples of successful nanoparticle theranostic agents already employed clinically, several undergoing clinical trials, and countless others emerging from preclinical studies, we are ushering in the era of nanomedicine. Smart, specific, and customizable, theranostic nanoparticles will soon—pending FDA approval—detect, treat, and prevent disease. MINT has been established to create a forum to discuss these advances and better integrate disciplines that develop and use nanoparticles for imaging and therapy.

**Acknowledgements.** We would like to thank the investigators who joined us as Founding Members of the MINT interest group for their valuable contribution to the field. Namely, Silvio Aime, James Basilion, Michelle Bradbury, Heike Daldrup-Link, Katherine Ferrara, Sam Gambir, Jan Grimm, Jesse Jokerst, Kimberly Kelly, Fabian Kiessling, Twan Lammers, Jonathan Liu, Matthias Nahrendorf, Vasilis Ntziachristos, Manuel Perez, Bernd Pichler, Mikhail G. Shapiro, Andrew Tsourkas, and Ralph Weissleder. The following funding sources (to M.F.K.) are acknowledged: NIH R01 EB017748 and K08 CA16396; M.F.K. is a Damon Runyon-Rachleff Innovator supported (in part) by the Damon Runyon Cancer Research Foundation (DRR-29-14); Pershing Square Sohn Prize by the Pershing Square Sohn Cancer Research Alliance; MSKCC Center for Molecular Imaging & Nanotechnology (CMINT) Grant; MSKCC Technology Development Grant; Mr. William H. and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research and The Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. Acknowledgements are also extended to the grant-funding support provided by the MSKCC NIH Core Grant (P30-CA008748).

## Compliance with Ethical Standards

### Conflict of Interest

M.F.K. is an inventor on several pending patents related to Raman nanoparticles, Raman detection, and theranostic hardware, as well as radiolabeling of silica particles, and is a cofounder of RIO Imaging, Inc., a startup company that has licensed several of these patents.

## References

- Bobo D, Robinson KJ, Islam J et al (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. *Pharm Res* 33:2373–2387
- Anselmo AC, Mitragotri S (2016) Nanoparticles in the clinic. *Bioeng Translational Med* 1:10–29
- Stylianopoulos T (2016) Intelligent drug delivery systems for the treatment of solid tumors. *Eur J Nanomed* 8:9–16
- Kircher MF, Willmann JK (2012) Molecular body imaging: MR imaging, CT, and US. Part II. Applications. *Radiology* 264:349–368
- Kircher MF, Willmann JK (2012) Molecular body imaging: MR imaging, CT, and US. Part I. Principles. *Radiology* 263:633–643
- Bashir MR, Bhatti L, Marin D, Nelson RC (2015) Emerging applications for ferumoxytol as a contrast agent in MRI. *J Magn Reson Imaging* 41:884–898
- Gaglia JL, Harisinghani M, Aganj I et al (2015) Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. *Proc Natl Acad Sci U S A* 112:2139–2144
- Kirschbaum K, Sonner JK, Zeller MW et al (2016) *In vivo* nanoparticle imaging of innate immune cells can serve as a marker of disease severity in a model of multiple sclerosis. *Proc Natl Acad Sci U S A* 113:13227–13232
- Deng L, Stafford JH, Liu SC et al (2016) SDF-1 blockade enhances anti-VEGF therapy of glioblastoma and can be monitored by MRI. *Neoplasia* 19:1–7
- Bryant LH Jr, Kim SJ, Hobson M et al (2016) Physicochemical characterization of ferumoxytol, heparin and protamine nanocomplexes for improved magnetic labeling of stem cells. *Nanomedicine*. doi:10.1016/j.nano.2016.07.011
- Klenk C, Gawande R, Uslu L et al (2014) Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. *Lancet Oncol* 15:275–285
- Zanganeh S, Hutter G, Spitler R et al (2016) Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. *Nat Nano* 11:986–994
- Pratt EC, Shaffer TM, Grimm J (2016) Nanoparticles and radiotracers: advances toward radionanomedicine. *Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology* 8:872–890
- Lee DS, Im H-J, Lee Y-S (2015) Radionanomedicine: widened perspectives of molecular theragnosis. *Nanomedicine: Nanotechnology, Bio Med* 11:795–810
- Goel S, Chen F, Ehlerding EB, Cai W (2014) Intrinsically radiolabeled nanoparticles: an emerging paradigm. *Small* 10:3825–3830
- Sun X, Huang X, Yan X et al (2014) Chelator-free <sup>64</sup>Cu-integrated gold nanomaterials for positron emission tomography imaging guided photothermal cancer therapy. *ACS Nano* 8:8438–8446
- Zhao Y, Sultan D, Detering L et al (2014) Copper-64-alloyed gold nanoparticles for cancer imaging: improved radiolabel stability and diagnostic accuracy. *Angew Chem Intl Ed* 53:156–159
- Guo W, Sun X, Jacobson O et al (2015) Intrinsically radioactive [<sup>64</sup>Cu]CuInS/ZnS quantum dots for PET and optical imaging: improved radiochemical stability and controllable Cerenkov luminescence. *ACS Nano* 9:488–495
- Sun X, Huang X, Guo J et al (2014) Self-illuminating <sup>64</sup>Cu-doped CdSe/ZnS nanocrystals for *in vivo* tumor imaging. *J Am Chem Soc* 136:1706–1709
- Shaffer TM, Harmsen S, Khwaja E et al (2016) Stable radiolabeling of sulfur-functionalized silica nanoparticles with copper-64. *Nano Lett* 16:5601–5604

21. Pressly ED, Pierce RA, Connal LA et al (2013) Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. *Bioconj Chem* 24:196–204
22. Gao F, Cai P, Yang W et al (2015) Ultrasmall [<sup>64</sup>Cu]Cu nanoclusters for targeting orthotopic lung tumors using accurate positron emission tomography imaging. *ACS Nano* 9:4976–4986
23. Hansen AE, Petersen AL, Henriksen JR et al (2015) Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper-64 liposomes. *ACS Nano* 9:6985–6995
24. Madru R, Tran TA, Axelsson J et al (2014) <sup>68</sup>Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multimodality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. *Am J Nucl Med Mol Imaging* 4:60–69
25. Frigell J, Garcia I, Gomez-Vallejo V, Llop J, Penades S (2014) <sup>68</sup>Ga-labeled gold glyconanoparticles for exploring blood-brain barrier permeability: preparation, biodistribution studies, and improved brain uptake via neuropeptide conjugation. *J Am Chem Soc* 136:449–457
26. Thorek DL, Ulmert D, Diop NF et al (2014) Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. *Nat Commun* 5:3097
27. Shaffer TM, Wall MA, Harmsen S et al (2015) Silica nanoparticles as substrates for chelator-free labeling of oxophilic radioisotopes. *Nano Lett* 15:864–868
28. Zeng J, Jia B, Qiao R et al (2014) In situ <sup>111</sup>In-doping for achieving biocompatible and non-leachable <sup>111</sup>In-labeled Fe<sub>3</sub>O<sub>4</sub> nanoparticles. *Chem Commun* 50:2170–2172
29. Shukla R, Chanda N, Zambre A et al (2012) Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. *Proc Natl Acad Sci* 109:12426–12431
30. Black KCL, Wang Y, Luehmann HP et al (2014) Radioactive <sup>198</sup>Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. *ACS Nano* 8:4385–4394
31. Majmudar MD, Yoo J, Keliher EJ et al (2013) Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. *Circ Res* 112:755–61
32. Perez-Medina C, Tang J, Abdel-Atti D et al (2015) PET imaging of tumor-associated macrophages with <sup>89</sup>Zr-labeled high-density lipoprotein nanoparticles. *J Nucl Med* 56:1272–1277
33. Keliher EJ, Yoo J, Nahrendorf M et al (2011) <sup>89</sup>Zr labeled dextran nanoparticles enable in vivo macrophage imaging. *Bioconj Chem* 22:2383–2389
34. Benezra M, Penate-Medina O, Zanzonico PB et al (2011) Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. *J Clin Invest* 121:2768–2780
35. Phillips E, Penate-Medina O, Zanzonico PB et al (2014) Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. *Sci Transl Med* 6:260ra149–260ra149
36. Hill TK, Mohs AM (2016) Image-guided tumor surgery: will there be a role for fluorescent nanoparticles? Wiley interdisciplinary reviews Nanomed Nanobiotechnol 8:498–511
37. Kamila S, McEwan C, Costley D et al (2016) Diagnostic and therapeutic applications of quantum dots in nanomedicine. *Top Curr Chem* 370:203–224
38. Wang Y, Zhou K, Huang G et al (2014) A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. *Nat Mater* 13:204–212
39. Priem B, Tian C, Tang J, Zhao Y, Mulder WJ (2015) Fluorescent nanoparticles for the accurate detection of drug delivery. *Expert Opin Drug Deliv* 12:1881–1894
40. Nune SK, Gunda P, Thallapally PK et al (2009) Nanoparticles for biomedical imaging. *Expert Opin Drug Deliv* 6:1175–1194
41. Wu C, Bull B, Szymanski C et al (2008) Multicolor conjugated polymer dots for biological fluorescence imaging. *ACS Nano* 2:2415–2423
42. Sample V, Newman RH, Zhang J (2009) The structure and function of fluorescent proteins. *Chem Soc Rev* 38:2852–2864
43. Yang J, Zhang Y, Gautam S et al (2009) Development of aliphatic biodegradable photoluminescent polymers. *Proc Natl Acad Sci U S A* 106:10086–10091
44. Zhao Y, Ye M, Chao Q et al (2009) Simultaneous detection of multifoed-borne pathogenic bacteria based on functionalized quantum dots coupled with immunomagnetic separation in food samples. *J Agric Food Chem* 57:517–524
45. Yan L, Zhang Y, Xu B, Tian W (2016) Fluorescent nanoparticles based on AIE fluorogens for bioimaging. *Nanoscale* 8:2471–2487
46. Geng J, Zhu Z, Qin W et al (2014) Near-infrared fluorescence amplified organic nanoparticles with aggregation-induced emission characteristics for in vivo imaging. *Nanoscale* 6:939–945
47. Tummers QR, Hoogstins CE, Peters AA et al (2015) The value of intraoperative near-infrared fluorescence imaging based on enhanced permeability and retention of indocyanine green: feasibility and false-positives in ovarian cancer. *PLoS One* 10:e0129766
48. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 7:392–401
49. Andreou C, Kishore SA, Kircher MF (2015) Surface-enhanced Raman spectroscopy: a new modality for cancer imaging. *J Nucl Med* 56:1295–1299
50. Andreou C, Neuschmelting V, Tschaharganeh D-F et al (2016) Imaging of liver tumors using surface-enhanced Raman scattering nanoparticles. *ACS Nano* 10:5015–5026
51. Garai E, Sensarn S, Zavaleta CL et al (2013) High-sensitivity, real-time, ratiometric imaging of surface-enhanced Raman scattering nanoparticles with a clinically translatable Raman endoscope device. *J Biomed Opt* 18:096008
52. Harmsen S, Huang R, Wall MA et al (2015) Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. *Sci Transl Med* 7:271ra277
53. Spaliviero M, Harmsen S, Huang R et al (2016) Detection of lymph node metastases with SERRS nanoparticles. *Mol Imaging Biol* 18:677–685
54. Kircher MF, de la Zerda A, Jokerst JV et al (2012) A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. *Nat Med* 18:829–834
55. Harmsen S, Bedics MA, Wall MA et al (2015) Rational design of a chalcogenopyrylium-based surface-enhanced resonance Raman scattering nanoprobe with attomolar sensitivity. *Nat Commun* 6:6570
56. Huang R, Harmsen S, Samii JM et al (2016) High precision imaging of microscopic spread of glioblastoma with a targeted ultrasensitive SERRS molecular imaging probe. *Theranostics* 6:1075–1084
57. Karabeber H, Huang R, Iacono P et al (2014) Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. *ACS Nano* 8:9755–9766
58. Oseledchik A, Andreou C, Wall MA, Kircher MF (2017) Folate-targeted surface-enhanced resonance Raman scattering nanoprobe Ratiometry for detection of microscopic ovarian cancer. *ACS Nano*. doi:10.1021/acsnano.6b06796
59. Nayak TR, Andreou C, Oseledchik A et al (2016) Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases. *Nanoscale*. doi:10.1039/C6NR08217C
60. Lemaster JE, Jokerst JV (2016) What is new in nanoparticle-based photoacoustic imaging? Wiley Interdisciplinary Reviews: Nanomed Nanobiotechnol. doi:10.1002/wnan.1404
61. Cheheltani R, Ezzibdeh RM, Chhour P et al (2016) Tunable, biodegradable gold nanoparticles as contrast agents for computed tomography and photoacoustic imaging. *Biomaterials* 102:87–97
62. Cheng X, Sun R, Yin L et al (2016) Light-triggered assembly of gold nanoparticles for photothermal therapy and photoacoustic imaging of tumors in vivo. *Adv Mater*. doi:10.1002/adma.201604894
63. Dixon AJ, Hu S, Klibanov AL, Hossack JA (2015) Oscillatory dynamics and in vivo photoacoustic imaging performance of plasmonic nanoparticle-coated microbubbles. *Small* 11:3066–3077
64. Jing L, Liang X, Deng Z et al (2014) Prussian blue coated gold nanoparticles for simultaneous photoacoustic/CT bimodal imaging and photothermal ablation of cancer. *Biomaterials* 35:5814–5821
65. Liu Y, He J, Yang K et al (2015) Folding up of gold nanoparticle strings into plasmonic vesicles for enhanced photoacoustic imaging. *Angew Chem* 127:16035–16038
66. Yang H-W, Liu H-L, Li M-L et al (2013) Magnetic gold-nanorod/PNIPAAmMA nanoparticles for dual magnetic resonance and photoacoustic imaging and targeted photothermal therapy. *Biomaterials* 34:5651–5660

67. Egusquiaguirre SP, Beziere N, Pedraz JL et al (2015) Optoacoustic imaging enabled biodistribution study of cationic polymeric biodegradable nanoparticles. *Contrast Media Mol Imaging* 10:421–427
68. Jokerst JV, Van de Sompel D, Bohndiek SE, Gambhir SS (2014) Cellulose nanoparticles are a biodegradable photoacoustic contrast agent for use in living mice. *Photoacoustics* 2:119–127
69. Li K, Liu B (2014) Polymer-encapsulated organic nanoparticles for fluorescence and photoacoustic imaging. *Chem Soc Rev* 43:6570–6597
70. Lu HD, Wilson BK, Heinmiller A et al (2016) Narrow absorption NIR wavelength organic nanoparticles enable multiplexed photoacoustic imaging. *ACS Applied Mater Interfaces* 8:14379–14388
71. Xie C, Upputuri PK, Zhen X et al (2017) Self-quenched semiconducting polymer nanoparticles for amplified in vivo photoacoustic imaging. *Biomaterials* 119:1–8
72. Yan Y, Yang Q, Wang J et al (2017) Heteropoly blue doped polymer nanoparticles: an efficient theranostic agent for targeted photoacoustic imaging and near-infrared photothermal therapy in vivo. *J Mater Chem B* 5:382–387
73. Maji SK, Sreejith S, Joseph J et al (2014) Upconversion nanoparticles as a contrast agent for photoacoustic imaging in live mice. *Adv Mater* 26:5633–5638
74. Cai X, Liu X, Liao LD et al (2016) Encapsulated conjugated oligomer nanoparticles for real-time photoacoustic sentinel lymph node imaging and targeted photothermal therapy. *Small* 12:4873–4880
75. Chen Q, Liu X, Zeng J et al (2016) Albumin-NIR dye self-assembled nanoparticles for photoacoustic pH imaging and pH-responsive photothermal therapy effective for large tumors. *Biomaterials* 98:23–30
76. Ding K, Zeng J, Jing L et al (2015) Aqueous synthesis of PEGylated copper sulfide nanoparticles for photoacoustic imaging of tumors. *Nanoscale* 7:11075–11081
77. Gao S, Wang G, Qin Z et al (2017) Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy. *Biomaterials* 112:324–335
78. Ho I-T, Sessler JL, Gambhir SS, Jokerst JV (2015) Parts per billion detection of uranium with a porphyrinoid-containing nanoparticle and in vivo photoacoustic imaging. *Analyst* 140:3731–3737
79. Jin Y, Li Y, Ma X et al (2014) Encapsulating tantalum oxide into polypyrrole nanoparticles for X-ray CT/photoacoustic bimodal imaging-guided photothermal ablation of cancer. *Biomaterials* 35:5795–5804
80. Ku G, Zhou M, Song S et al (2012) Copper sulfide nanoparticles as a new class of photoacoustic contrast agent for deep tissue imaging at 1064 nm. *ACS Nano* 6:7489–7496
81. Liu R, Jing L, Peng D et al (2015) Manganese (II) chelate functionalized copper sulfide nanoparticles for efficient magnetic resonance/photoacoustic dual-modal imaging guided photothermal therapy. *Theranostics* 5:1144–1153
82. Lyu Y, Fang Y, Miao Q et al (2016) Intraparticle molecular orbital engineering of semiconducting polymer nanoparticles as amplified theranostics for in vivo photoacoustic imaging and photothermal therapy. *ACS Nano* 10:4472–4481
83. Pu K, Mei J, Jokerst JV et al (2015) Diketopyrrolopyrrole-based semiconducting polymer nanoparticles for in vivo photoacoustic imaging. *Adva Mater* 27:5184–5190
84. Pu K, Shuhendler AJ, Jokerst JV et al (2014) Semiconducting polymer nanoparticles as photoacoustic molecular imaging probes in living mice. *Nature Nanotechnol* 9:233–239
85. Sun C, Wen L, Zeng J et al (2016) One-pot solventless preparation of PEGylated black phosphorus nanoparticles for photoacoustic imaging and photothermal therapy of cancer. *Biomaterials* 91:81–89
86. Tsyboulski DA, Liopo AV, Su R et al (2014) Enabling in vivo measurements of nanoparticle concentrations with three-dimensional optoacoustic tomography. *J Biophotonics* 7:581–588
87. Yu J, Yang C, Li J et al (2014) Multifunctional Fe<sub>3</sub>C<sub>2</sub> nanoparticles: a targeted theranostic platform for magnetic resonance imaging and photoacoustic tomography-guided photothermal therapy. *Adv Mater* 26:4114–4120
88. Bogdanov AA Jr, Dixon AJ, Gupta S et al (2016) Synthesis and testing of modular dual-modality nanoparticles for magnetic resonance and multispectral photoacoustic imaging. *Bioconjug Chem* 27:383–390
89. Grootendorst DJ, Jose J, Fratila RM et al (2013) Evaluation of superparamagnetic iron oxide nanoparticles (Endorem®) as a photoacoustic contrast agent for intra-operative nodal staging. *Contrast Media Mol Imaging* 8:83–91
90. Xi L, Grobmyer SR, Zhou G et al (2014) Molecular photoacoustic tomography of breast cancer using receptor targeted magnetic iron oxide nanoparticles as contrast agents. *J Biophotonics* 7:401–409
91. Gurka MK, Pender D, Chuong P et al (2016) Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography. *J Control Release* 231:60–67
92. Li J, Arnal B, Wei C-W et al (2015) Magneto-optical nanoparticles for cyclic magnetomotive photoacoustic imaging. *ACS Nano* 9:1964–1976
93. Das S, Thorek DLJ, Grimm J (2014) Cerenkov imaging. *Adv Cancer Res* 124:213–234
94. Thorek DL, Riedl CC, Grimm J (2014) Clinical Cerenkov luminescence imaging of <sup>18</sup>F-FDG. *J Nucl Med* 55:95–98
95. Czupryna J, Kachur AV, Blankemeyer E et al (2015) Cerenkov-specific contrast agents for detection of pH in vivo. *J Nucl Med* 56:483–488
96. Grootendorst MR, Cariati M, Kothari A et al (2016) Cerenkov luminescence imaging (CLI) for image-guided cancer surgery. *Clin Translational Imaging* 4:353–366
97. Kotagiri N, Sudlow G, Akers W, Achilefu S (2015) Depth-independent phototherapy using Cerenkov radiation and titanium dioxide nanoparticles. *J Nucl Med* 56:643–643
98. Black KCL, Ibricevic A, Gunsten SP et al (2016) In vivo fate tracking of degradable nanoparticles for lung gene transfer using PET and Cerenkov imaging. *Biomaterials* 98:53–63
99. Kamkaew A, Cheng L, Goel S et al (2016) Cerenkov radiation induced photodynamic therapy using Chlorin e6-loaded hollow mesoporous silica nanoparticles. *ACS Applied Mater Interfaces* 8:26630–26637
100. Lee SB, Ahn SB, Lee SW et al (2016) Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and Cerenkov luminescence. *NPG Asia Materials* 8:e281
101. Lee SB, Yoon G, Lee SW et al (2016) Combined positron emission tomography and Cerenkov luminescence imaging of sentinel lymph nodes using PEGylated radionuclide-embedded gold nanoparticles. *Small* 12:4894–4901
102. Hu Z, Qu Y, Wang K et al (2015) In vivo nanoparticle-mediated radiopharmaceutical-excited fluorescence molecular imaging. *Nature Commun* 6:7560
103. Thorek DL, Ogirala A, Beattie BJ, Grimm J (2013) Quantitative imaging of disease signatures through radioactive decay signal conversion. *Nat Med* 19:1345–1350
104. Xu R, Zhang G, Mai J et al (2016) An injectable nanoparticle generator enhances delivery of cancer therapeutics. *Nat Biotech* 34:414–418
105. Zhang R, Fan Q, Yang M et al (2015) Engineering melanin nanoparticles as an efficient drug-delivery system for imaging-guided chemotherapy. *Adv Mater* 27:5063–5069
106. Yan Y, Liu L, Xiong H et al (2016) Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. *Proc Natl Acad Sci U S A* 113:E5702–E5710
107. Zheng D, Giljohann DA, Chen DL et al (2012) Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. *Proc Natl Acad Sci U S A* 109:11975–11980
108. Alidori S, Akhavan N, Thorek DLJ et al (2016) Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. *Sci Translational Med* 8:331ra339
109. Gobin AM, Lee MH, Halas NJ et al (2007) Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. *Nano Lett* 7:1929–1934
110. Stern JM, Stanfield J, Kabbani W et al (2008) Selective prostate cancer thermal ablation with laser activated gold nanoshells. *J Urology* 179:748–753
111. Schwartz JA, Shetty AM, Price RE et al (2009) Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. *Cancer Res* 69:1659



112. Loo C, Lowery A, Halas N et al (2005) Immunotargeted nanoshells for integrated cancer imaging and therapy. *Nano Lett* 5:709–711
113. Cardinal J, Klune JR, Chory E et al (2008) Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. *Surgery* 144:125–132
114. Gannon CJ, Patra CR, Bhattacharya R et al (2008) Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. *J Nanobiotechnol* 6:2
115. Kotagiri N, Sudlow GP, Akers WJ, Achilefu S (2015) Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers. *Nat Nano* 10:370–379
116. Idris NM, Gnanasamandhan MK, Zhang J et al (2012) In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. *Nat Med* 18:1580–1585
117. Maier-Hauff K, Ulrich F, Nestler D et al (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. *J Neuro-Oncol* 103:317–324
118. Johannsen M, Gneveckow U, Taymoorian K et al (2007) Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. *International J Hyperthermia* 23:315–323
119. van Landeghem FKH, Maier-Hauff K, Jordan A et al (2009) Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. *Biomaterials* 30:52–57
120. Hayashi K, Nakamura M, Sakamoto W et al (2013) Superparamagnetic nanoparticle clusters for cancer theranostics combining magnetic resonance imaging and hyperthermia treatment. *Theranostics* 3:366–376
121. Jordan A, Scholz R, Maier-Hauff K et al (2006) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. *J Neuro-Oncol* 78:7–14
122. Kalber TL, Ordidge KL, Southern P et al (2016) Hyperthermia treatment of tumors by mesenchymal stem cell-delivered superparamagnetic iron oxide nanoparticles. *Int J Nanomedicine* 11:1973–1983
123. Timbie K, Nance E, Zhang C, et al. (2014) Ultrasound-mediated nanoparticle delivery across the blood-brain barrier (676.17). *FASEB J* (suppl 676.17) 28
124. Rapoport N, Payne A, Dillon C et al (2013) Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model. *J Ther Ultrasound* 1:11
125. Morch Y, Hansen R, Berg S et al (2015) Nanoparticle-stabilized microbubbles for multimodal imaging and drug delivery. *Contrast Media Mol Imaging* 10:356–366
126. Min HS, Son S, You DG et al (2016) Chemical gas-generating nanoparticles for tumor-targeted ultrasound imaging and ultrasound-triggered drug delivery. *Biomaterials* 108:57–70
127. Stephan MT, Moon JJ, Um SH et al (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. *Nat Med* 16:1035–1041
128. Chen Q, Xu L, Liang C et al (2016) Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. *Nat Commun* 7:13193
129. Fadel TR, Sharp FA, Vudattu N et al (2014) A carbon nanotube-polymer composite for T-cell therapy. *Nat Nano* 9:639–647
130. McLaughlin MF, Robertson D, Pevsner PH et al (2014) LnPO<sub>4</sub> nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy. *Cancer Biother Radiopharmacol* 29:34–41
131. McLaughlin MF, Woodward J, Boll RA et al (2013) Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. *PLoS One* 8:e54531
132. Chen J, Zhu S, Tong L et al (2014) Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. *BMC Cancer* 14:114–114
133. Klutz K, Schaffert D, Willhauck MJ et al (2011) Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. *Mol Therapy* 19:676–685
134. Satterlee AB, Yuan H, Huang L (2015) A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. *J Control Release* 217:170–182
135. Das M, Dattar SR, Singh RP, Jain S (2013) Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic acid-multiwalled carbon nanotube conjugate. *Mol Pharmacol* 10:2543–2557
136. Zhang X-D, Luo Z, Chen J et al (2014) Ultrasmall Au10–12(SG)10–12 nanomolecules for high tumor specificity and cancer radiotherapy. *Adv Mater* 26:4565–4568
137. Al Zaki A, Joh D, Cheng Z et al (2014) Gold-loaded polymeric micelles for computed tomography-guided radiation therapy treatment and radiosensitization. *ACS Nano* 8:104–112
138. Hainfeld JF, Smilowitz HM, O'Connor MJ et al (2013) Gold nanoparticle imaging and radiotherapy of brain tumors in mice. *Nanomed* 8:1601–1609
139. Popovtzer A, Mizrahi A, Motiei M et al (2016) Actively targeted gold nanoparticles as novel radiosensitizer agents: an in vivo head and neck cancer model. *Nanoscale* 8:2678–2685
140. Liu P, Huang Z, Chen Z et al (2013) Silver nanoparticles: a novel radiation sensitizer for glioma? *Nanoscale* 5:11829–11836
141. Moendarbari S, Tekade R, Mulgaonkar A et al (2016) Theranostic nanoseeds for efficacious internal radiation therapy of unresectable solid tumors. *Sci Reports* 6:20614
142. Yi X, Yang K, Liang C et al (2015) Imaging-guided combined photothermal and radiotherapy to treat subcutaneous and metastatic tumors using iodine-131-doped copper sulfide nanoparticles. *Adv Functional Mater* 25:4689–4699
143. Chen F, Rieffel J, Chen G et al (2015) Hexamodal imaging in vivo with nanoparticles. *J Nucl Med* 56:56–56
144. Rieffel J, Chen F, Kim J et al (2015) Hexamodal imaging with porphyrin-phospholipid-coated upconversion nanoparticles. *Adv Mater* 27:1785–1790
145. Conde J, Oliva N, Zhang Y, Artzi N (2016) Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. *Nat Mater* 15:1128–1138
146. Kaittanis C, Shaffer TM, Bolaender A et al (2015) Multifunctional MRI/PET nanobeacons derived from the in situ self-assembly of translational polymers and clinical cargo through coalescent intermolecular forces. *Nano Lett* 15:8032–8043
147. Kaittanis C, Shaffer TM, Ogirala A et al (2014) Environment-responsive nanophores for therapy and treatment monitoring via molecular MRI quenching. *Nat Commun* 5:3384
148. Miller MA, Gadde S, Pfirschke C et al (2015) Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. *Sci Transl Med* 7:314ra183–314ra183
149. van de Ven AL, Abdollahi B, Martinez CJ et al (2013) Modeling of nanotherapeutics delivery based on tumor perfusion. *New J Phys* 15:55004
150. Wu L, Cai X, Nelson K et al (2013) A green synthesis of carbon nanoparticles from honey and their use in real-time photoacoustic imaging. *Nano Res* 6:312–325
151. Sharma N, Pinnaka AK, Raje M et al (2012) Exploitation of marine bacteria for production of gold nanoparticles. *Microb Cell Factories* 11:86
152. Kikuchi F, Kato Y, Furihata K et al (2016) Formation of gold nanoparticles by glycolipids of *Lactobacillus casei*. *Sci Rep* 6:34626
153. Parodi A, Quattrocchi N, van de Ven AL et al (2013) Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. *Nat Nanotechnol* 8:61–68
154. Braun GB, Friman T, Pang HB et al (2014) Etchable plasmonic nanoparticle probes to image and quantify cellular internalization. *Nat Mater* 13:904–911
155. Kim SE, Zhang L, Ma K et al (2016) Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. *Nat Nano* 11:977–985
156. Li M, Li L, Zhan C, Kohane DS (2016) Core-shell nanostars for multimodal therapy and imaging. *Theranostics* 6:2306–2313
157. Chen F, Ellison PA, Lewis CM et al (2013) Chelator-free synthesis of a dual-modality PET/MRI agent. *Angewandte Chemie (International ed in English)* 52:13319–13323
158. Chakravarty R, Valdovinos HF, Chen F et al (2014) Intrinsically germanium-69-labeled iron oxide nanoparticles: synthesis and in-vivo dual-modality PET/MR imaging. *Adv Mater* 26:5119–5123

159. Siddiqi KS, Ur Rahman A, Tajuddin HA (2016) Biogenic fabrication of iron/iron oxide nanoparticles and their application. *Nanoscale Res Lett* 11:498
160. Tafoya MA, Madi S, Sillerud LO (2016) Superparamagnetic nanoparticle-enhanced MRI of Alzheimer's disease plaques and activated microglia in 3X transgenic mouse brains: contrast optimization. *J Magn Reson Imaging*. doi:10.1002/jmri.25563
161. Madru R, Tran TA, Axelsson J et al (2013) <sup>68</sup>Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multimodality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. *Am J Nucl Med Mol Imaging* 4:60–69
162. Aghighi M, Golovko D, Ansari C et al (2015) Imaging tumor necrosis with ferumoxytol. *PLoS One* 10:e0142665
163. Khurana A, Chapelin F, Beck G et al (2013) Iron administration before stem cell harvest enables MR imaging tracking after transplantation. *Radiology* 269:186–197
164. Sciallero C, Balbi L, Paradossi G, Trucco A (2016) Magnetic resonance and ultrasound contrast imaging of polymer-shelled microbubbles loaded with iron oxide nanoparticles. *R Soc Open Sci* 3:160063
165. Nissinen T, Nakki S, Laakso H et al (2016) Tailored dual PEGylation of inorganic porous nanocarriers for extremely long blood circulation in vivo. *ACS Appl Mater Interfaces* 8:32723–32731
166. Cui Y, Zhang C, Luo R et al (2016) Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles. *Int J Nanomedicine* 11:5671–5682
167. Jaidev LR, Chellappan DR, Bhavsar DV et al (2017) Multifunctional nanoparticles as theranostic agents for the treatment & imaging of pancreatic cancer. *Acta Biomater* 49:422–433
168. Liu Q, Sun Y, Li C et al (2011) <sup>18</sup>F-labeled magnetic-upconversion nanophosphors via rare-earth cation-assisted ligand assembly. *ACS Nano* 5:3146–3157
169. Xiang Z, Yang X, Xu J et al (2017) Tumor detection using magnetosome nanoparticles functionalized with a newly screened EGFR/HER2 targeting peptide. *Biomaterials* 115:53–64
170. Wang Y, Liu Y, Luehmann H et al (2013) Radioluminescent gold nanocages with controlled radioactivity for real-time in vivo imaging. *Nano Lett* 13:581–585
171. Perez-Campana C, Gomez-Vallejo V, Puigivila M et al (2013) Biodistribution of different sized nanoparticles assessed by positron emission tomography: a general strategy for direct activation of metal oxide particles. *ACS Nano* 7:3498–3505
172. Perez-Campana C, Gomez-Vallejo V, Martin A et al (2012) Tracing nanoparticles in vivo: a new general synthesis of positron emitting metal oxide nanoparticles by proton beam activation. *Analyst* 137:4902–4906
173. Zhou M, Zhang R, Huang M et al (2010) A chelator-free multifunctional [<sup>64</sup>Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. *J Am Chem Soc* 132:15351–15358
174. Thorek DLJ, Das S, Grimm J (2014) Molecular imaging using nanoparticle quenchers of Cerenkov luminescence. *Small* 10:3729–3734
175. Lin X, Xie J, Niu G et al (2011) Chimeric ferritin nanocages for multiple function loading and multimodal imaging. *Nano Lett* 11:814–819
176. Mead BP, Mastorakos P, Suk JS et al (2016) Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. *J Control Release* 223:109–117
177. Ma X, Kang F, Xu F et al (2013) Enhancement of Cerenkov luminescence imaging by dual excitation of Er<sup>3+</sup>, Yb<sup>3+</sup>-doped rare-earth microparticles. *PLoS One* 8:e77926
178. Zhenhua H, Liu M, Guo H et al (2016) Image-guided cancer surgery using a novel nanoparticle-mediated radiopharmaceutical-excited fluorescence molecular imaging. *J Nucl Med* 57:59–59
179. Lee B-R, Ko HK, Ryu JH et al (2016) Engineered human ferritin nanoparticles for direct delivery of tumor antigens to lymph node and cancer immunotherapy. *Sci Reports* 6:35182